-
Link Pharma Chem Ltd. Announces Appointment of New CEO
Link Pharma Chem Ltd. (LPC), a leading global manufacturer of generic pharmaceuticals, today announced the appointment of Dr. John Smith as its new Chief Executive Officer (CEO), effective immediately.
-
Link Pharma Chem Ltd. Reports Strong Financial Results for 2022
Link Pharma Chem Ltd. (LPC) today reported strong financial results for the year ended December 31, 2022. The company reported a 10% increase in revenue to $1.5 billion and a 15% increase in net income to $200 million.
-
Link Pharma Chem Ltd. Launches New Product for Treatment of Diabetes
Link Pharma Chem Ltd. (LPC) today announced the launch of a new product for the treatment of diabetes. The new product, called Glucophage, is a generic version of the popular diabetes medication metformin.
-
Link Pharma Chem Ltd. Appoints New Vice President of Sales
Dr. John Smith, a seasoned pharmaceutical industry executive with over 20 years of experience, has been appointed as the new Vice President of Sales at Link Pharma Chem Ltd. In his new role, Dr. Smith will be responsible for leading the company's global sales efforts and driving revenue growth.
-
Link Pharma Chem Ltd. Announces New Drug Approval
The U.S. Food and Drug Administration (FDA) has approved a new drug developed by Link Pharma Chem Ltd. The drug, which is indicated for the treatment of a rare genetic disorder, is expected to be available to patients in the coming months.
-
Link Pharma Chem Ltd. Partners with Leading Research Institution
Link Pharma Chem Ltd. has announced a new partnership with a leading research institution to develop new treatments for cancer. The partnership will bring together the expertise of both organizations to accelerate the development of new therapies.
-
Special offer on all our products
Get 20% off on all our products, starting today! Use code "SUMMER" at checkout.
-
Free shipping on orders over $100
We are now offering free shipping on all orders over $100! Get your hands on some great deals today.
-
New product launch: Vitamin C serum
We are excited to announce the launch of our new Vitamin C serum! This serum is packed with antioxidants and nutrients that will help you achieve brighter, healthier skin.
-
Link Pharma Chem To Expand Production Capacity of API Plant At Hyderabad
Link Pharma Chem announced that the Company is pleased to inform that, the Board of Directors of the Company at its meeting held on Wednesday, 15th June, 2023 has approved the following:
Proposal for expansion of API (Active Pharmaceutical Ingredients) manufacturing facility at IDA Nacharam, Hyderabad-500076, Telangana.
-
Link Pharma Chem Receives USFDA Approval For Its New Drug Application (ANDA)
Link Pharma Chem announced that the Company has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Prednisone tablets USP, 20 mg, (an anti-inflammatory corticosteroid).
-
Link Pharma Chem's Board Approves Stock Split
Link Pharma Chem announced that the Board of Directors of the Company at its meeting held on Thursday, 11th May, 2023 approved the sub-division of every one equity share of face value of Rs. 10/- (Rupees Ten only) each into 5 (Five) equity shares of face value of Rs. 2/- (Rupees Two only) each.
-
Link Pharma Chem Ltd. Announces Positive Results from Phase II Clinical Trial of LPC-002 for the Treatment of Mild to Moderate Alzheimer's Disease
Link Pharma Chem Ltd. (Link Pharma) today announced positive topline results from a Phase II clinical trial evaluating the efficacy and safety of LPC-002, an investigational oral therapy for the treatment of mild to moderate Alzheimer's disease (AD). The trial met its primary endpoint, demonstrating a statistically significant improvement in cognitive function in patients treated with LPC-002 compared to placebo.
-
Link Pharma Chem Ltd. Receives FDA Orphan Drug Designation for LPC-002 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Link Pharma Chem Ltd. (Link Pharma) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to LPC-002, an investigational oral therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Orphan Drug Designation is intended to provide incentives to develop drugs for rare diseases that affect fewer than 200,000 people in the United States.
-
Link Pharma Chem Ltd. Strengthens Leadership Team with Appointment of Dr. John Smith as Chief Medical Officer
Link Pharma Chem Ltd. (Link Pharma) today announced the appointment of Dr. John Smith as Chief Medical Officer. Dr. Smith brings over 20 years of experience in the pharmaceutical industry, including leadership roles in clinical development, regulatory affairs, and medical affairs.
-
Link Pharma Chem Ltd. Appoints Dr. Robert B. D'alessandro as Chief Scientific Officer
Link Pharma Chem Ltd. (LPC), a cGMP contract manufacturing organization (CMO) for APIs and drug products, today announced the appointment of Dr. Robert B. D'Alessandro as its Chief Scientific Officer (CSO).
-
Link Pharma Chem Ltd. Announces Expansion of API Manufacturing Facility in India
Link Pharma Chem Ltd. (LPC), a leading contract manufacturing organization (CMO) for APIs and drug products, today announced the expansion of its API manufacturing facility in India.
-
Link Pharma Chem Ltd. Awarded ISO 9001:2015 Certification for its API and Drug Product Manufacturing Facility
Link Pharma Chem Ltd. (LPC), a leading contract manufacturing organization (CMO) for APIs and drug products, today announced that it has been awarded ISO 9001:2015 certification for its API and drug product manufacturing facility in India.
